公开(公告)号：WO2010008587A3

公开(公告)日：2010-09-30

申请号：PCT/US2009004150

申请日：2009-07-17

Applicant: STC UNM ,  PANGANIBAN ANTONITO T ,  MIR MOHAMMAD A

Inventor： PANGANIBAN ANTONITO T ,  MIR MOHAMMAD A

IPC: C12N15/67 ,  C07K14/175

CPC classification number: C12N15/67 ,  C07K14/005 ,  C12N2760/12122 ,  C12N2830/60

Abstract: The present invention is directed to a system to significantly increase the expression of genes of interest, and in particular proteins and polypeptide products. Expression of hantavirus nucleocapsid protein (N) by itself results in augmented translational expression of diverse genes. The mechanism of this augmentation relies on the ability of N to replace the cellular cap binding complex to attain more efficient translation initiation- the result being great mRNA production and greater protein/polypeptide production. The inventors have also recently found that inclusion of a 5' untranslated leader region (viral UTR) from a viral RNA, in conjunction with N, leads to even more robust expression. This mechanism appears to involve recognition of the viral UTR by the N to provide even more robust protein production. Thus, a general strategy for expression of any gene would be to generate significant quantities of mRNA containing the viral UTR from a strong promoter, and then to allow translation of mRNA of a gene product in the presence of N. Even a modest increase in the production of commercially desirable proteins is a goal in industry.

Abstract translation: 本发明涉及显着增加感兴趣的基因，特别是蛋白质和多肽产物的表达的系统。 汉坦病毒核衣壳蛋白（N）本身的表达导致不同基因的增强的翻译表达。 这种增加的机制依赖于N代替细胞帽结合复合物以获得更有效的翻译起始的能力，其结果是大的mRNA产生和更大的蛋白质/多肽生产。 发明人还最近发现，与N结合从病毒RNA中包含5'非翻译前导区（病毒UTR）导致更强的表达。 这种机制似乎涉及N的识别病毒UTR以提供更强大的蛋白质生产。 因此，用于表达任何基因的一般策略将是从强启动子产生含有病毒UTR的大量mRNA，然后允许在N存在下翻译基因产物的mRNA。即使适度增加 商业上需要的蛋白质的生产是工业中的一个目标。

公开(公告)号：WO2010074794A2

公开(公告)日：2010-07-01

申请号：PCT/US2009059849

申请日：2009-10-07

Applicant: STC UNM ,  KISIEL WALTER

Inventor： KISIEL WALTER

IPC: C07K14/47 ,  A61K38/17 ,  C12N15/12

CPC classification number: C07K14/8114 ,  A61K38/00 ,  A61K47/64

Abstract: Isolated polypeptides, nucleic acids, and methods relating to cellular internalization of materials are described herein. Generally, the isolated polypeptides include a membrane transduction domain of human tissue factor pathway inhibitor-2 (TFPI-2). In some cases, the isolated polypeptide can be a fusion peptide that includes a membrane transduction domain of human TFPI-2 and a heterologous peptide domain. The nucleic acids include nucleic acids that encode the isolated polypeptides described herein. The methods generally include providing a composition that includes a membrane transduction domain of human TFPI-2 coupled to a material, and contacting the composition with a cell under conditions effective to permit the cell to internalize the composition.

Abstract translation: 本文描述了与材料的细胞内化有关的分离的多肽，核酸和方法。 通常，分离的多肽包括人组织因子途径抑制剂-2（TFPI-2）的膜转导结构域。 在一些情况下，分离的多肽可以是包含人TFPI-2的膜转导结构域和异源肽结构域的融合肽。 核酸包括编码本文所述分离的多肽的核酸。 所述方法通常包括提供包含与材料偶联的人TFPI-2的膜转导结构域的组合物，并在有效允许细胞内化组合物的条件下使组合物与细胞接触。

公开(公告)号：WO2009148623A3

公开(公告)日：2010-03-25

申请号：PCT/US2009003438

申请日：2009-06-05

Applicant: STC UNM ,  THOMPSON TODD A ,  MACKENZIE DEBRA ,  OPREA TUDOR I ,  SKLAR LARRY A ,  EDWARDS BRUCE S ,  HAYNES MARK

Inventor： THOMPSON TODD A ,  MACKENZIE DEBRA ,  OPREA TUDOR I ,  SKLAR LARRY A ,  EDWARDS BRUCE S ,  HAYNES MARK

IPC: A61K31/445 ,  A61K31/165 ,  A61P35/00

CPC classification number: A61K31/437 ,  A61K31/135 ,  A61K31/165 ,  A61K31/445 ,  A61K45/06 ,  A61N5/10

Abstract: A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed.

Abstract translation: 治疗和/或预防癌症的方法包括在癌细胞中引起增加的细胞内颗粒度的给药剂，至少足以抑制这种细胞增殖的量，优选以足以导致癌细胞死亡的量。 该方法特别涉及难治性癌症，特别是激素难治性前列腺癌。 所鉴定的试剂导致癌细胞中细胞内的粒度增加，并将粘附的癌细胞转化为非粘附的癌细胞，导致癌细胞死亡。 使用本发明，癌细胞在相对低的药物浓度下经历增加的细胞内粒度，同时也抑制细胞增殖。 增加的浓度导致粘附的癌细胞转化为非粘附的癌细胞，然后转移到细胞死亡。 虽然癌细胞降解和死亡的确切机制尚未完全了解，但治疗的癌细胞（包括难治性前列腺癌细胞）通过自噬机制给予细胞死亡的指示。 还公开了与目前公开的方法相关的药物组合物。

公开(公告)号：WO2009097174A2

公开(公告)日：2009-08-06

申请号：PCT/US2009030304

申请日：2009-01-07

Applicant: STC UNM ,  SITDIKOV RAVIL ,  IVNITSKIV DMITRI ,  LOPEZ GABRIEL ,  RAMIREZ BRIANNA ,  ATANASSOV PLAMEN

Inventor： SITDIKOV RAVIL ,  IVNITSKIV DMITRI ,  LOPEZ GABRIEL ,  RAMIREZ BRIANNA ,  ATANASSOV PLAMEN

IPC: G01N27/327 ,  G01N27/28 ,  G01N27/41 ,  G01N33/48

CPC classification number: G01N33/557 ,  B82Y5/00 ,  G01N2333/11

Abstract: A simple, fast, selective and highly sensitive electrochemical method assay and disposable device for detection of viruses, bacteria, proteins, DNA, and/or organic/inorganic compounds. The sensor has a multi-layered construction, with each successive layer performing a different function. The design further allows for the packing of numerous microscopic electrode transducers onto the small footprint of a biochip device, allowing for a high-density array of sensors.

Abstract translation: 用于检测病毒，细菌，蛋白质，DNA和/或有机/无机化合物的简单，快速，选择性和高度灵敏的电化学方法测定和一次性装置。 该传感器具有多层结构，每个连续的层执行不同的功能。 该设计进一步允许将许多微观电极换能器包装到生物芯片装置的小占地面积上，从而允许高密度阵列的传感器。

公开(公告)号：WO2008057505A3

公开(公告)日：2008-08-28

申请号：PCT/US2007023311

申请日：2007-11-06

Applicant: STC UNM ,  DU CLOS TERRY W ,  MOLD CAROLYN

Inventor： DU CLOS TERRY W ,  MOLD CAROLYN

IPC: A61K35/14

CPC classification number: A61K35/15 ,  A61K35/28 ,  A61K38/1745 ,  A61K2300/00

Abstract: The present invention relates to the use of suppressive macrophage or dendritic cells (activated with C-reactive protein or CRP-related compounds), for the treatment of various disease states and conditions associated with immune thrombocytopenic purpura (ITP) and/or systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with systemic lupus erythematosus or ITP will have an outbreak is an additional aspect of the present invention. In the case of ITP, methods of the present invention are used to increase platelet counts in the treated patient. In addition, in the case of ITP, the present invention relates to the use of CRP or a CRP-related compound in the absence of suppressive macrophages for the treatment of ITP.

Abstract translation: 本发明涉及抑制性巨噬细胞或树突状细胞（用C反应蛋白或CRP相关化合物活化）用于治疗与免疫血小板减少性紫癜（ITP）和/或系统性红斑狼疮相关的各种疾病状态和病症 （SLE），包括皮肤（盘状）的狼疮，关节，肺和肾的系统性红斑狼疮，血液病症，包括溶血性贫血和低淋巴细胞计数，淋巴结病和CNS作用，包括记忆丧失，癫痫发作和精神病， 本文另有公开。 在本发明的另一方面，减少与系统性红斑狼疮或ITP相关的疾病状态或疾病爆发危险的患者将发生爆发的可能性是本发明的另外的方面。 在ITP的情况下，本发明的方法用于增加治疗患者的血小板计数。 此外，在ITP的情况下，本发明涉及在不存在抑制性巨噬细胞用于治疗ITP的情况下使用CRP或CRP相关化合物。

公开(公告)号：WO2007103152A3

公开(公告)日：2008-05-02

申请号：PCT/US2007005312

申请日：2007-03-01

Applicant: STC UNM ,  SMYTH HUGH ,  TRUMAN CHARLES RANDALL

Inventor： SMYTH HUGH ,  TRUMAN CHARLES RANDALL

IPC: A61M15/00

CPC classification number: A61M15/0065 ,  A61M15/0003 ,  A61M15/001 ,  A61M15/0028 ,  A61M15/0043 ,  A61M15/0045 ,  A61M15/0051 ,  A61M15/0055 ,  A61M15/0068 ,  A61M2202/064 ,  A61M2205/8275 ,  A61M2206/14 ,  A61M2206/16

Abstract: The present invention comprises a dry powder inhaler (DPI) that uses a patient's inhalation flow to concentrate energy in an aeroelastic element for deaggregation and dispersion of a powder dose. The result is a DPI that delivers a dose independent of inspiratory abilities of the patient, solving a major problem of conventional DPIs. Increased tension on the aeroelastic element causes higher frequency vibrations and improved powder dispersion. The tension of the aeroelastic element can be modified prior to dispensing the DPI to the patient, allowing for individualization for single patients or groups of patients. In addition, the DPI has features that increase the turbulence of the airflow as it passes through the device, further increasing the dispersion and deaggregation of the powder. The DPI can hold a single dose or multiple doses. The powder doses can be dispensed directly onto the aeroelastic element, or may be in adjacent blister packaging.

Abstract translation: 本发明包括干粉吸入器（DPI），其使用患者的吸入流将能量集中在气动弹性元件中用于粉末剂量的解聚和分散。 其结果是DPI能够独立于患者的吸气能力，解决常规DPI的主要问题。 气动弹性元件上的增加的张力会导致更高的频率振动和改善的粉末分散。 在将DPI分配给患者之前，可以修改气动弹性元件的张力，从而允许单个患者或患者组的个体化。 此外，DPI具有增加气流在通过装置时的湍流的特征，进一步增加了粉末的分散和解聚。 DPI可以持续单剂量或多剂量。 粉末剂量可以直接分配到气动弹性元件上，或者可以在相邻的吸塑包装中。

公开(公告)号：WO2008024427A3

公开(公告)日：2008-04-17

申请号：PCT/US2007018614

申请日：2007-08-23

Applicant: STC UNM ,  PEABODY DAVID S ,  CHACKERIAN BRYCE

Inventor： PEABODY DAVID S ,  CHACKERIAN BRYCE

IPC: A61K48/00 ,  A61K39/12

CPC classification number: C12N15/1037 ,  A61K2039/5256 ,  A61K2039/5258 ,  C07K14/005 ,  C12N2740/16122 ,  C12N2795/18123 ,  C40B40/02

Abstract: The invention is directed to virus-like particles (VLPs)of an RNA bacteriophage that (a) comprises a coat polypeptide of said phage modified by insertion of a heterologous peptide that is displayed on said VLP and (b) encapsidates said bacteriophage mRNA as well as populations of these VLPs, and their uses. The invention is further directed to VLPs that encapsidate heterologous substances, as well as populations of these VLPs and their uses.

Abstract translation: 本发明涉及RNA噬菌体的病毒样颗粒（VLP），其（a）包含通过插入在所述VLP上显示的异源肽修饰的所述噬菌体的外壳多肽，和（b）还包封所述噬菌体mRNA 作为这些VLP的群体及其用途。 本发明还涉及包裹异源物质的VLP以及这些VLP的群体及其用途。

公开(公告)号：WO2007019180A3

公开(公告)日：2008-04-10

申请号：PCT/US2006030130

申请日：2006-08-02

Applicant: STC UNM ,  CHEMDIV INC ,  ARROWHEAD CT INC ,  PROSSNITZ ERIC R ,  TKATCHENKO SERGEY E ,  REVANKAR CHETANA M ,  SKLAR LARRY A ,  ARTERBURN JEFFREY B ,  CIMINO DANIEL F ,  OPREA TUDOR I ,  BOLOGA CRISTIAN-GEORGE ,  EDWARDS BRUCE S ,  KISELYOV ALEXANDOR ,  YOUNG SUSAN M

Inventor： PROSSNITZ ERIC R ,  TKATCHENKO SERGEY E ,  REVANKAR CHETANA M ,  SKLAR LARRY A ,  ARTERBURN JEFFREY B ,  CIMINO DANIEL F ,  OPREA TUDOR I ,  BOLOGA CRISTIAN-GEORGE ,  EDWARDS BRUCE S ,  KISELYOV ALEXANDOR ,  YOUNG SUSAN M

IPC: A61K31/435 ,  C07D215/04 ,  C07D215/12 ,  C07D215/16 ,  C07D221/06 ,  C07D405/10 ,  C07D491/048 ,  C07D491/052 ,  C07D491/147

CPC classification number: C07D221/16 ,  C07D405/04 ,  C07D405/14

Abstract: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERa and ERß). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases which are mediated through one or more of these receptors include cancer (particularly breast, reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometreitis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease, as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

Abstract translation: 本发明在分子生物学/药理学领域，并提供调节GPR30以及经典雌激素受体α和β（ERα和ERβ）的作用的化合物。 这些化合物可以用作一种或多种所公开的雌激素受体的激动剂和/或拮抗剂。 通过这些受体中的一种或多种介导的疾病包括癌症（特别是乳腺，生殖和其他激素依赖性癌症，白血病，结肠癌，前列腺癌），生殖（泌尿 - 泌尿）包括子宫内膜炎，前列腺炎，多囊卵巢综合征，膀胱 控制，激素相关疾病，听觉障碍，心血管疾病，包括潮热和大量出汗，高血压，中风，肥胖，骨质疏松症，血液病，血管疾病或诸如静脉血栓形成，动脉粥样硬化等疾病，以及许多其他疾病和中枢和 周围神经系统，包括抑郁症，失眠，焦虑，多发性硬化，神经病变，神经变性疾病如帕金森病和阿尔茨海默病，以及炎性肠病，克罗恩病，腹腔（腹腔）疾病和肠道相关疾病。 用于预防或减少性交后怀孕的可能性的避孕指示是本发明的另一方面。

公开(公告)号：WO2007050661A3

公开(公告)日：2007-09-20

申请号：PCT/US2006041583

申请日：2006-10-26

Applicant: STC UNM ,  DU CLOS TERRY W ,  MOLD CAROLYN

Inventor： DU CLOS TERRY W ,  MOLD CAROLYN

IPC: C07K14/435

CPC classification number: A61K38/1709

Abstract: The present invention relates to the use of C-reactive protein, its mutants, metabolites and polypeptides and related compounds thereof for the treatment of various disease states and conditions associated with systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein, hi another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with systemic lupus erythematosus will have an outbreak is an additional aspect of the present invention.

Abstract translation: 本发明涉及C-反应蛋白，其突变体，代谢物和多肽及其相关化合物用于治疗与系统性红斑狼疮（SLE）有关的各种疾病状态和病症（包括皮肤的狼疮（盘状））的用途， 在本发明的另一方面中，关节，肺和肾的系统性红斑狼疮，包括溶血性贫血和低淋巴细胞计数的淋巴细胞病症，淋巴结病和CNS作用（包括记忆丧失，癫痫发作和精神病） 在有可能爆发与系统性红斑狼疮相关的疾病状态或病症的患者发生暴发的可能性是本发明的另一方面。

公开(公告)号：WO2005044334A2

公开(公告)日：2005-05-19

申请号：PCT/US2004035161

申请日：2004-10-22

Applicant: STC UNM ,  SIBBITT WILMER L JR

Inventor： SIBBITT WILMER L JR

IPC: A61M5/32 ,  A61M25/06 ,  A61M

CPC classification number: A61M25/0637 ,  A61M5/3272 ,  A61M25/0631 ,  A61M2205/59

Abstract: A butterfly needle assembly has a needle and a shield with wings integral to either the needle or the shield. The wings have aesthetically pleasing patterns to distract the patient during treatment. The mechanical design of the needle and shield juncture improves the stability of the assembly when inserted into a patient, as well as allowing the assembly to be disengaged with a single hand to help the caregiver avoid a needle "stick" and prevent the spread of diseases.

Abstract translation: 蝴蝶针组件具有针和屏蔽件，其具有与针或屏蔽件成一体的翼。 这些翅膀具有美观的模式，以便在治疗期间分散患者的注意力。 针和屏蔽接头的机械设计提高了组装在插入患者体内的稳定性，并且允许组装单手脱开，以帮助护理者避免针“粘”并防止疾病传播 。